FNMA heads into the back half of July nursing an 11% one-month decline to $6.11, with the stock down nearly 2% on the week even as its closest peer FMCC managed a small gain of 0.5%.
The divergence with Freddie Mac is the week's sharpest tension. FNMA and FMCC move together with a correlation above 97% over most timeframes, so the gap — modest in absolute terms — flags that something idiosyncratic is at work on Fannie's side. The most plausible explanation is valuation compression: the price-to-earnings multiple has expanded dramatically to around 1,430x on a trailing basis, a function of near-zero earnings yield rather than genuine growth. Price-to-book sits at negative 4.65, a structural artifact of conservatorship accounting that makes traditional valuation tools almost meaningless here. What's being repriced isn't fundamentals — it's the probability distribution around GSE reform timelines.
Short interest and borrow conditions are unremarkable, which is itself informative. Bears hold just 1.3% of the free float in short positions, down about 9% over the past month and roughly unchanged week-on-week. Cost to borrow is close to flat at around 0.50% — actually cheaper than it was a week ago, following a 16% decline in that rate. The lending pool remains well stocked, with availability running at 456%, meaning nearly five shares are available for every one already borrowed. This is a name where the argument is almost entirely about political and regulatory outcomes, not a crowded short or a squeeze setup.
The analyst picture is divided, and recent coverage is thin. Mizuho initiated with an Outperform and a $10 target in early May, making the case that privatization momentum provides a re-rating catalyst. Keefe, Bruyette & Woods sits on the other side with an Underperform, trimming its target from $10 to $8.50 in April — its analyst has been the most consistent bear over several years, cycling through multiple rating changes as the conservatorship saga has dragged on. The consensus mean target of $9.85 implies meaningful upside from current levels, but the Deutsche Bank $20 target initiated last September looks aggressive relative to where the stock actually trades and may reflect a bull-case scenario on full privatization rather than a base case. Factor scores offer little conviction — EPS momentum ranks in just the 3rd percentile over the past 30 days, while the short score at 40 sits in the 43rd percentile, neither extreme.
Institutional ownership is highly concentrated. Pershing Square holds just over 2% of shares, making Bill Ackman the dominant outside investor in a position that has been a long-running thesis on GSE release from conservatorship. Capital Research holds another 1.4%. Neither reported changes in their most recent filings, and the insider data is stale — the last meaningful transaction dates to May 2025, a pair of nominal director trades under $55,000 each that carried minimal significance scores.
Earnings history in the snapshot lacks price-reaction data, but the next scheduled event is October 27. What to watch between now and then is straightforward: any concrete language from Treasury or the FHFA on conservatorship exit terms, changes in the 30-year mortgage rate trajectory, and whether Pershing Square makes any public commentary on the timeline — because on FNMA, the policy calendar does more work than the income statement.
See the live data behind this article on ORTEX.
Open FNMA on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
